Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.
Cancer Discov
Authors | |
Keywords | |
Abstract | The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods. |
Year of Publication | 2013
|
Journal | Cancer Discov
|
Volume | 3
|
Issue | 10
|
Pages | 1108-12
|
Date Published | 2013 Oct
|
ISSN | 2159-8290
|
URL | |
DOI | 10.1158/2159-8290.CD-13-0219
|
PubMed ID | 24124232
|
PubMed Central ID | PMC3800055
|
Links | |
Grant list | U24 CA160034 / CA / NCI NIH HHS / United States
U24 CA159988 / CA / NCI NIH HHS / United States
U24CA159988 / CA / NCI NIH HHS / United States
U24CA160036 / CA / NCI NIH HHS / United States
U24 CA160036 / CA / NCI NIH HHS / United States
U24 CA160019 / CA / NCI NIH HHS / United States
U24 CA160035 / CA / NCI NIH HHS / United States
U24CA160034 / CA / NCI NIH HHS / United States
U24CA160035 / CA / NCI NIH HHS / United States
U24CA160019 / CA / NCI NIH HHS / United States
|